RTRX insider filings
Travere Therapeutics, Inc. — 19 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2020-11-25. Screen RTRX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for RTRX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Travere Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2020-11-25 | 4 | Clague Laura — Chief Financial Officer | Grant/award (A): 7,500 @ $0 · Sale (S): 3,750 @ $23.86 · Sale (S): 3,750 @ $22.72 | EDGAR |
| 2020-11-17 | 4 | ROTE WILLIAM E. — Senior Vice President, R&D | Sale (S): 2,500 @ $23.96 | EDGAR |
| 2020-11-17 | 4 | Clague Laura — Chief Financial Officer | Sale (S): 7,500 @ $23.98 | EDGAR |
| 2020-11-17 | 4 | REED ELIZABETH E — SVP, GC & Corporate Secretary | Sale (S): 2,500 @ $23.98 | EDGAR |
| 2020-11-13 | 4 | ROTE WILLIAM E. — Senior Vice President, R&D | Grant/award (A): 5,000 @ $0 · Sale (S): 2,500 @ $23.62 | EDGAR |
| 2020-11-13 | 4 | Clague Laura — Chief Financial Officer | Grant/award (A): 15,000 @ $0 · Sale (S): 7,500 @ $23.61 | EDGAR |
| 2020-11-13 | 4 | REED ELIZABETH E — SVP, GC & Corporate Secretary | Grant/award (A): 5,000 @ $0 · Sale (S): 2,500 @ $23.62 | EDGAR |
| 2020-11-06 | 4 | ASELAGE STEVE — Director | Sale (S): 2,500 @ $21.26 · Sale (S): 20,625 @ $23 | EDGAR |
| 2020-10-05 | 4 | Heerma Peter — Chief Commercial Officer | Sale (S): 2,188 @ $18.90 · Sale (S): 2,188 @ $19.35 | EDGAR |
| 2020-09-23 | 4 | ROTE WILLIAM E. — Senior Vice President, R&D | Sale (S): 1,500 @ $18.48 | EDGAR |
| 2020-09-23 | 4 | Rosenberg Noah L. — Chief Medical Officer | Sale (S): 750 @ $18.48 | EDGAR |
| 2020-09-23 | 4 | Clague Laura — Chief Financial Officer | Sale (S): 1,500 @ $18.48 | EDGAR |
| 2020-09-23 | 4 | REED ELIZABETH E — SVP, GC & Corporate Secretary | Sale (S): 1,500 @ $18.48 | EDGAR |
| 2020-09-22 | 4 | ROTE WILLIAM E. — Senior Vice President, R&D | Grant/award (A): 3,000 @ $0 · Sale (S): 1,500 @ $18.59 | EDGAR |
| 2020-09-22 | 4 | Rosenberg Noah L. — Chief Medical Officer | Grant/award (A): 3,000 @ $0 · Sale (S): 750 @ $18.59 | EDGAR |
| 2020-09-22 | 4 | Dube Eric M — Chief Executive Officer, Director | Grant/award (A): 25,000 @ $0 · Grant/award (A): 3,000 @ $0 · Sale (S): 9,240 @ $19.28 · Sale (S): 1,565 @ $19.29 | EDGAR |
| 2020-09-22 | 4 | Clague Laura — Chief Financial Officer | Grant/award (A): 3,000 @ $0 · Sale (S): 1,500 @ $18.59 | EDGAR |
| 2020-09-22 | 4 | REED ELIZABETH E — SVP, GC & Corporate Secretary | Grant/award (A): 3,000 @ $0 · Sale (S): 1,500 @ $18.59 | EDGAR |
| 2020-08-06 | 4 | ASELAGE STEVE — Director | Sale (S): 2,500 @ $19.68 | EDGAR |
Recent 8-K events — Travere Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-02 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-14 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RTRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs